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Major vault protein suppresses obesity and
atherosclerosis through inhibiting IKK–NF-κB
signaling mediated inﬂammation
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Macrophage-orchestrated, low-grade chronic inﬂammation plays a pivotal role in obesity and
atherogenesis. However, the underlying regulatory mechanisms remain incompletely
understood. Here, we identify major vault protein (MVP), the main component of unique
cellular ribonucleoprotein particles, as a suppressor for NF-κB signaling in macrophages. Both
global and myeloid-speciﬁc MVP gene knockout aggravates high-fat diet induced obesity,
insulin resistance, hepatic steatosis and atherosclerosis in mice. The exacerbated metabolic
disorders caused by MVP deﬁciency are accompanied with increased macrophage inﬁltration
and heightened inﬂammatory responses in the microenvironments. In vitro studies reveal that
MVP interacts with TRAF6 preventing its recruitment to IRAK1 and subsequent oligomer-
ization and ubiquitination. Overexpression of MVP and its α-helical domain inhibits the
activity of TRAF6 and suppresses macrophage inﬂammation. Our results demonstrate that
macrophage MVP constitutes a key constraint of NF-κB signaling thereby suppressing
metabolic diseases.
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Low-grade, chronic inﬂammation is implicated in manyimmune-metabolic diseases including obesity and athero-sclerosis1–4. The macrophage is an important immune cell
orchestrating chronic inﬂammatory responses by sensing and
reacting to various stresses in metabolic organs including adipose
tissue, liver, and artery wall4–9. Inﬂammatory cytokines and
chemokines, such as tumor necrosis factor (TNF)-α, interleukin
(IL)-6, IL-1β, and C–C motif ligand-2 (CCL2), disrupt metabolic
homeostasis and the functions of metabolic cells and stromal
components1,2,4,5. Thus, inﬂammatory responses determine the
metabolic pathophysiological outcome in the diseased
microenvironment.
Inﬂammatory signaling in cells is composed of receptors, sig-
naling kinases, and effectors. Pattern recognition receptors (e.g.,
toll-like receptors, TLRs) play pivotal roles in both the initiation
and the resolution of inﬂammation10,11. For example, the acti-
vation of TLR4 can stimulate the myeloid differentiation primary
response gene 88 (MyD88)-dependent signaling and promotes
the assembly of a complex containing the interleukin 1 receptor-
associated kinase 1 (IRAK1) and the TNF receptor-associated
factor 6 (TRAF6), which results in the activation of IκB kinases
(IKKs) and, eventually, transcription factor nuclear factor κB
(NF-κB)11–14. IKK–NF-κB cascades have been implicated in
immune-mediated and inﬂammatory diseases15–18. As the
immune system needs to constantly strike a balance between
activation and inhibition to avoid detrimental and inappropriate
inﬂammatory responses, pro-inﬂammatory signaling like the NF-
κB pathway must be tightly regulated. Although the mechanisms
of NF-κB activation have been well studied, the intrinsic negative
regulatory mechanisms in the inﬂammatory response need to be
further explored.
Major vault protein (MVP) is the main component of cellular
ribonucleoprotein particles known as vaults19. The unique vault
structure, consisting of 78 MVP subunits, numerous copies of the
vault-associated proteins including vault poly(ADP-ribose)
polymerase (VPARP) and telomerase-associated protein-1
(TEP1), and small untranslated RNA (vRNA), is implicated in the
regulation of several cellular processes including nucleocyto-
plasmic transport, signaling transduction, cellular differentiation,
cell survival, and immune responses19–25. In the present study, we
investigate the role of MVP in metabolic inﬂammation. By using
several animal models of metabolic diseases, we identify macro-
phage MVP as an important suppressor of NF-κB activation by
preventing TRAF6 ubiquitination. This consequently inhibits NF-
κB pathway-related metabolic inﬂammation and attenuates
obesity-associated insulin resistance, hepatic steatosis, and
atherosclerosis. The discovery of MVP-mediated negative reg-
ulation of NF-κB may pave the way for clinical intervention
strategies for metabolic diseases.
Results
Macrophage MVP is up-regulated in obese adipose tissues.
Obesity is a central feature of metabolic diseases. To under-
stand the role of MVP in metabolic diseases, we ﬁrstly
determined the role of MVP in obesity. Obese male C57BL/6J
mice were generated by administering with a high-fat diet
(HFD) for 12 weeks. We found that obesity caused a sig-
niﬁcant increase of MVP in the epididymal white adipose
tissue (epiWAT) (Fig. 1a), particularly in the stromal vascular
fraction cells (SVFs) but not in the adipocytes of epiWAT
(Fig. 1b). This differential expression pattern of MVP was
reproduced in the isolated SVFs and adipocytes from epiWAT
by western blot analysis. Expression levels of MVP were found
to be dramatically higher in the isolated SVFs than in adipo-
cytes in both normal chow diet (CD)- and HFD-fed mice
(Fig. 1c). Immunoﬂuorescence staining revealed that MVP co-
localized mainly with CD68+ macrophages in the adipose
tissue (Fig. 1d). When F4/80+ macrophages were isolated
from epiWAT SVFs by ﬂow cytometry, we conﬁrmed the
HFD-induced overexpression of MVP in macrophages
(Fig. 1e). Consistently, signiﬁcant increased MVP levels were
detected in HFD-fed murine peritoneal macrophages (PMs)
compared with CD-fed murine PMs (Fig. 1f). MVP was also
up-regulated in gonadal WAT (gonWAT) macrophages and
PMs from the HFD-fed female mice (Supplementary Fig. 1a,
b), suggesting a similar expressional trend of MVP in both
male and female obese mice.
We next measured the expressional level of MVP in obese
human beings. Immunohistochemistry (IHC) staining showed
that the expression of MVP in the stromal compartment was
substantially increased in the visceral adipose tissue of overweight
or obese individuals compared with normal weight controls
(Fig. 1g, h). There was a co-localization of MVP with CD68+
macrophages in human visceral adipose tissues (Fig. 1i). MVP
expression was much higher in the CD14+ macrophages isolated
from visceral adipose tissue in overweight or obese persons than
in normal weight individuals (Fig. 1j).
In summary, up-regulation of MVP expression in macrophages
of visceral adipose tissues was correlated with obesity in both
humans and mice, suggesting that MVP be involved in obesity-
associated inﬂammation.
MVP deﬁciency aggravates obesity and metabolic disorders.
We further deleted the MVP gene (MVP KO) in male mice which
were fed with either a CD or a HFD for 7 weeks together with the
age- and sex-matched wild-type (WT) littermates. MVP deﬁ-
ciency did not inﬂuence murine body weight and glycolipid
metabolism under CD-fed conditions (Supplementary Fig. 2).
However, upon HFD challenge, MVP KO mice gained more
weight (Fig. 2a) and displayed a higher weight of multiple adipose
depots (Fig. 2b) including epi, mesenteric (m), perirenal (peri),
subcutaneous (sub) WAT, and brown adipose tissue (BAT) than
WT mice. Larger adipocyte size and lower expression of adipo-
nectin (ADIPOQ) and leptin (LEP), the known important adi-
pokines produced by functional adipocytes, were detected in
HFD-fed MVP KO mice (Fig. 2c–e).
Obesity impairs glucose metabolism in the body. In the present
study, we found that MVP deﬁciency exacerbated HFD-induced
high blood glucose (Fig. 2f) and glucose-induced hyperinsuline-
mia (Fig. 2g). Furthermore, MVP deﬁciency impaired glucose
tolerance and insulin tolerance in mice (Fig. 2h, i) in conjunction
with suppressed phosphorylation of AKT, a readout of intracel-
lular insulin signaling, in epiWAT, liver, and skeletal muscle
(Fig. 2j). These data suggest that MVP deﬁciency may aggravate
obesity-associated insulin resistance in mice.
We also examined the impact of MVP deﬁciency on lipid
metabolism. It was shown that plasma levels of nonesteriﬁed
fatty acid (NEFA), triglycerides (TG), and total cholesterol
(TCH) were signiﬁcantly increased in HFD-fed MVP KO mice
compared with WT mice (Fig. 2k, l). Hepatic steatosis is nearly
a uniform feature of obesity. Indeed, we found that MVP
deﬁciency caused a dramatic increase in liver weight, intra-
hepatic TG and TCH contents, and plasma levels of AST and
ALT (Fig. 2m–o). Consistently, a dramatic change in the
overall liver morphology with accumulation of large droplet-
like structures (Fig. 2p, q) and higher expression of the fatty
acid synthesis and uptake genes (FASN, SCD1, SREBP-1C,
PPARγ, and CD36) in the liver (Fig. 2r) were observed in MVP
KO mice. HFD-fed female MVP KO mice exhibited similar
phenotypic changes to those male mice (Supplementary
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09588-x
2 NATURE COMMUNICATIONS |         (2019) 10:1801 | https://doi.org/10.1038/s41467-019-09588-x | www.nature.com/naturecommunications
MVP
HFD
a
CD
α-Tubulin
CD HFDCD HFD
Adipocyte SVF
MVP
α-Tubulin
c
d
CD68MVP
Perilipin Merged+DAPI
CD HFDb
CD HFD
MVP
e
F4/80+ SVF
f
HFDCD
α-Tubulin
MVP
α-Tubulin
130
55
kDa
130
55
kDa
130
55
kDa 130
55
kDa
CD68MVP Perilipin Merged+DAPI
Normal weight Overweight/obeseg
h
i
j
CD HFD
0.0
0.1
0.2
0.3
0.4
0.5 *
M
VP
/α
-
Tu
bu
lin
 
CD HFD CD HFD
0.0
0.2
0.4
0.6
0.8
**
**
Adipocyte SVF
*
M
VP
/α
-
Tu
bu
lin
 
CD HFD
0.0
0.5
1.0
1.5 **
M
VP
/α
-
Tu
bu
lin
CD HFD
0.0
0.2
0.4
0.6
0.8
**
M
VP
/α
-
Tu
bu
lin
0
1
2
3
4
5
Pe
rc
en
ta
ge
 o
f M
VP
po
sit
ive
 a
re
a 
to
 to
ta
l a
re
a 
Nor
mal
 we
ight
Ove
rwe
ight
/obe
se
Nor
mal
 we
ight
Ove
rwe
ight
/obe
se
**
0
10
20
30
40
50
*
M
VP
/G
AP
DH
 
m
R
N
A
Fig. 1 MVP expression is up-regulated in macrophages from obese mice and human beings. Male C57BL/6J mice were fed a CD or a HFD for 12 weeks.
aWestern blot analysis of MVP expression in epiWAT (n= 6). b IHC staining of MVP in epiWAT. Scale bars, 50 μm (top) and 20 μm (bottom). cWestern
blot analysis of MVP expression in the adipocytes and SVFs isolated from epiWAT (n= 3). d Immunoﬂuorescence images of staining with antibodies
against CD68 (green), MVP (red), and Perilipin (purple) in epiWAT of HFD-fed mice. Nuclei were stained with DAPI (blue). Scale bars, 20 μm. e Western
blot analysis of MVP expression in sorted F4/80+ macrophages isolated from epiWAT SVFs (n= 3). f Western blot analysis of MVP in PMs (n= 6).
g, h IHC staining (g) and quantitative analysis (h) of MVP in the visceral adipose tissue from normal weight donors and individuals with overweight or
obesity (n= 5). Scale bars, 50 μm (top) and 20 μm (bottom). i Representative immunoﬂuorescence images of staining with antibodies against CD68
(green), MVP (red), and Perilipin (purple) in visceral adipose tissue of overweight or obese individuals. Nuclei were stained with DAPI (blue). Scale bars,
20 μm. j mRNA level of MVP in CD14+ macrophages isolated from the visceral adipose tissue SVFs of normal weight (18.5≤ BMI < 24, n= 15) and
overweight (24≤ BMI < 28) or obese (BMI≥ 28) (n= 24) subjects. Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 by Student’s t test or
ANOVA with post hoc test
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Fig. 2 MVP deﬁciency deteriorates HFD-induced metabolic disorders in mice. Male WT and MVP KO mice were fed a HFD for 7 weeks. a The percentage of
body weight gain in WT andMVP KO mice (n= 11). b Depot mass of epi, mesentery (m), perirenal (peri), subcutaneous (sub) WAT and BAT in WT andMVP
KO mice (n= 8). c H&E staining of epiWAT fromWT andMVP KO mice. Scale bars, 50 μm. d Quantiﬁcation of adipocyte size in epiWAT of WT andMVP KO
mice (n= 6). e mRNA levels of ADIPOQ and LEP in epiWAT from WT and MVP KO mice (n= 6). f Fasting blood glucose in WT and MVP KO mice (n= 10).
g Basal- and stimulated-insulin levels in WT and MVP KO mice (n= 8). h, i GTT and ITT in WT and MVP KO mice (n= 5). j Western blot of AKT
phosphorylation in the murine epiWAT, liver, and skeletal muscle stimulated by insulin. k, l Plasma levels of NEFA (k), TG and TCH (l) in WT andMVP KOmice
(n= 8).m, nMurine liver tissues were retrieved after 7 weeks of HFD feeding and their wet weights (m), liver TG and TCH (n) levels were determined (n= 8).
o Plasma levels of AST and ALT in mice (n= 8). p H&E (top) and Oil Red O (bottom) staining of representative liver sections obtained from HFD-fedWT (left)
and MVP KO (right) mice. Scale bars, 100 μm. q Quantiﬁcation of Oil Red O stained area of liver (n= 5). r mRNA levels of lipid metabolism-related genes in
livers from WT and MVP KO mice (n= 6). Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 by Student’s t test or ANOVA with post hoc test
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Fig. 3). Therefore, MVP deﬁciency may deteriorate HFD-
induced obesity and obesity-associated metabolic disorders
including insulin resistance, dysregulation of glycolipid
metabolism, and liver steatosis in mice.
Myeloid MVP deﬁciency exacerbates metabolic disorders. Since
MVP predominantly localized in macrophages in obese adipose
tissues, we further generated a mouse model with myeloid-
speciﬁc deletion of MVP (MacKO, MVPﬂox/ﬂoxLyz2-Cre) by
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establishing MVPﬂox/ﬂox mice that were crossed with Lyz2-Cre
mice (Supplementary Fig. 4a-b) to investigate the role of mac-
rophage MVP in the pathogenesis of metabolic disorders. The
absence of MVP was detected in both bone marrow-derived
macrophages (BMDMs) and PMs (Fig. 3a) but not in other tis-
sues (Supplementary Fig. 4c). Similar to MVP KO mice, MacKO
mice fed a normal chow diet showed minimal changes in body
weight and glycolipid metabolism (Supplementary Fig. 5). How-
ever, challenge with 12 weeks of HFD feeding resulted in a greater
body weight gain in MacKO mice compared to control (MacWT,
MVPﬂox/ﬂox) littermates (Fig. 3b). Consistently, MacKO mice
displayed higher levels of various adipose depots weight (Fig. 3c),
larger average adipocyte size (Fig. 3d, e), decreased levels of
ADIPOQ and LEP in the epiWAT (Fig. 3f). These results indicate
that myeloid MVP deﬁciency, speciﬁcally in macrophages, may
exacerbate HFD-induced obesity in mice.
MVP deletion in macrophages also exacerbated HFD-induced
insulin resistance (Fig. 3g–k), hyperlipidaemia (Fig. 3l, m) and
liver steatosis (Fig. 3n–r) in mice. The pro-steatotic effects by
macrophage MVP deﬁciency were presumably attributed to up-
regulation of fatty acid synthesis and uptake genes (FASN, CD36)
and down-regulation of fatty acid β-oxidation genes (CPT-1α,
LCAD, and PDK4) in the liver (Fig. 3s). These data clearly
demonstrate that macrophage MVP deﬁciency exhibited similar
phenotypic effects in mice as the global MVP knockout. MVP in
macrophages may play an important role in antagonizing obesity
and obesity-associated metabolic disorders.
MVP deﬁciency aggravates metabolic inﬂammation. To explore
the mechanisms underlying the antagonizing effects of MVP on
metabolic disorders, we examined the relationship between MVP
deﬁciency and inﬂammation. IHC analysis revealed that CD68+
macrophages in epiWAT were signiﬁcantly increased in HFD-fed
MVP KO mice compared with WT control group (Fig. 4a). FACS
measurements showed that the adipose tissues from obese MVP
KO mice contained more SVFs (Fig. 4b) and macrophages
(Fig. 4c, d). The pro-inﬂammatory cytokines TNF-α and IL-1β
and chemokines CCL2 and CCL3 were obviously increased in
epiWAT, subWAT, BAT, and liver of HFD-fed MVP KO mice
(Fig. 4e–h). The plasma levels of TNF-α and IL-1β were also
increased consistently (Fig. 4j). Furthermore, the pro-
inﬂammatory mediators were signiﬁcantly increased in F4/80+
macrophages isolated from epiWAT of HFD-fed MVP KO mice
(Fig. 4i), suggesting that the macrophage be an important source
for pro-inﬂammatory mediators in the obese MVP KO mice.
We further validated the role of macrophage MVP in
inﬂammatory responses by using the MacKO mice models. As
expected, the phenotypes displayed by the MacKO mice were
similar to those of MVP KO mice in the obesity-induced
inﬂammation (Fig. 4k–t). Taken together, our results suggest that
MVP may inhibit macrophage-orchestrated inﬂammatory
responses in obese mice.
MVP deﬁciency promotes atherosclerosis. Atherosclerosis is
also a metabolic disease in which inﬂammation is involved in
the whole process of pathogenesis4,7,18. We found that MVP
expression was up-regulated in the atherosclerotic plaques
induced by western diet (WD) administered for 10 weeks to
ApoE knockout (ApoEKO) mice (Supplementary Fig. 6a-b).
MVP was mainly expressed in CD68+ macrophages in the
mouse aortic roots (Supplementary Fig. 6c). In order to
investigate the impact of MVP on atherosclerosis, we gener-
ated the MVP and ApoE double knockout (MVPKOApoEKO)
mice. After feeding the mice with a WD for 10 weeks, we did
not observe signiﬁcant difference in serum lipid levels between
MVPKOApoEKO mice and MVPWTApoEKO littermates (Sup-
plementary Fig. 6d). However, atherosclerotic lesion in the
aorta was increased in MVPKOApoEKO mice in comparison
with MVPWTApoEKO littermates (Fig. 5a, d). MVPKOApoEKO
mice suffered from larger lesions (Fig. 5b, e) with more CD68
+ plaque area (Fig. 5c, f), suggesting that MVP deletion may
promote atherosclerosis in mice.
To further understand the role of macrophage MVP in
atherosclerosis, we generated myeloid-speciﬁc MVP deﬁciency
and ApoE knockout mice (MVPMacKOApoEKO, MVPﬂox/ﬂoxA-
poEKOLyz2-Cre) and the littermates (MVPMacWTApoEKO,
MVPﬂox/ﬂoxApoEKO) by crossing MVPﬂox/ﬂox mice with Lyz2-
Cre mice and ApoEKO mice. After feeding on a WD for 12 weeks,
MVPMacKOApoEKO mice exhibited similar atherosclerotic lesion
characteristics (Fig. 5g–l) and plasma lipids levels (Supplementary
Fig. 6e) as MVPKOApoEKO mice. These results reveal that the
MVP deﬁciency, or predominantly MVP deﬁciency in macro-
phages, may be a promoter of atherogenesis in mice.
MVP deﬁciency stimulates inﬂammation in atherosclerosis.
The observation that more CD68+ macrophages in MVP KO
atherosclerotic lesions compelled us to further investigate the
role of MVP in macrophage accumulation. We found the Ly-
6Chi pro-inﬂammatory monocytes labeled by ﬂuorescent
beads, representing the newly recruited monocytes26,27, were
dramatically increased in the MVPKOApoEKO atherosclerotic
lesions (Fig. 5m, n). In addition, the total peritoneal cells and
F4/80+ macrophages elicited by thioglycollate, an inducer of
inﬂammation, were also obviously increased in MVP KO
mice (Fig. 5o, p). These results indicate that MVP deﬁciency
may stimulate mono-macrophages recruitment to the artery
wall.
The macrophage inﬁltration in the tissue will most likely elicit
an inﬂammatory response. To validate it, we measured the
expression levels of multiple inﬂammatory mediators in the
Fig. 3 Myeloid MVP deletion deteriorates obesity and metabolic disorders. MacWT and MacKO male mice were fed a HFD for 12 weeks. a Western blot
analysis of MVP expression in PMs and BMDMs in WT, MacWT, and MacKO mice. b The percentage of body weight gain in MacWT (n= 9) and MacKO
(n= 10) mice during 12 weeks of HFD feeding. c Depot mass of epi, m, peri, subWAT, and BAT in MacWT and MacKO mice (n= 8). d Histological analysis
of epiWAT from MacWT and MacKO mice using H&E staining. Scale bars, 50 μm. e Quantiﬁcation of adipocyte size in epiWAT of MacWT and MacKO
HFD-fed mice (n= 6). f mRNA levels of ADIPOQ and LEP in epiWAT from MacWT and MacKO HFD-fed mice (n= 8). g Fasting blood glucose in MacWT
and MacKO mice (n= 9). h Basal- and stimulated- insulin levels in MacWT (n= 8) and MacKO (n= 6) mice. i, j GTT and ITT in MacWT and MacKO mice
(n= 6). k Western blot analysis of AKT phosphorylation in the murine epiWAT, liver, and skeletal muscle after insulin administration in vivo. l, m The
NEFA (l) (n= 6), TG and TCH (m) (n= 8) contents in the plasma of MacWT and MacKO mice. n, o Murine liver tissues were retrieved and their wet
weight (n), liver TG and TCH contents (o) were determined (n= 8). p Plasma levels of AST and ALT in MacWT and MacKO mice (n= 8). q H&E (top) and
Oil Red O (bottom) staining of representative liver sections obtained from HFD-fed MacWT (left) and MacKO (right) mice. Scale bars, 100 μm.
r Quantiﬁcation of Oil Red O stained area of liver (n= 5). s mRNA levels of lipid metabolism-related genes in livers from the HFD-fed MacWT and MacKO
mice (n= 6). Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 by Student’s t test or ANOVA with post hoc test
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mouse aortic lesions. A robust increase in pro-inﬂammatory
mediators such as TNF-α, IL-6, IL-1β, and CCL2 were observed in
MVPKOApoEKO mice and MVPMacKOApoEKO mice compared to
their control littermates (Fig. 5q, r). Consistently, plasma levels of
TNF-α, IL-1β, and CCL2 were also signiﬁcantly increased in
MVPMacKOApoEKO mice (Fig. 5s). Therefore, MVP deﬁciency
may result in vigorous inﬂammation in the artery wall. These
results were further corroborated by in vitro experiments, in
which administration of lipopolysaccharide (LPS) (Fig. 6a, b) but
not TNF-α (Supplementary Fig. 7a) caused a dramatically
increased production of TNF-α and CCL2 in the MVP KO
PMs compared with controls.
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MVP deﬁciency activates NF-κB signaling in macrophages. NF-
κB is a key transcription factor governing the expression of most
pro-inﬂammatory genes15. To understand how MVP modulates
inﬂammatory responses in macrophages, we examined the rela-
tionship between MVP and NF-κB signaling pathway. Figure 6c,
d shows that the loss of MVP strongly stimulated the phos-
phorylation of IKK and p65 and IκBα degradation, which led to
the translocation of the NF-κB complex into the nucleus to
initiate transcription. Indeed, we observed an enhanced nuclear
translocation of p65 in MVP KO macrophages (Fig. 6e–g). Fur-
thermore, when macrophages were treated with Bay11-7082, an
inhibitor of IκBα, MVP deﬁciency induced over-production of
TNF-α and CCL2 in PMs was effectively reversed (Fig. 6h).
Consistently, MVP deﬁciency also increased macrophage p-p65
in the mouse epiWAT (Supplementary Fig. 8a). Moreover, the
activated degree of NF-κB signaling and overproduction of
inﬂammatory cytokines were much stronger than that of the
MVP up-regulation in the obese murine epiWAT macrophages
(Supplementary Fig. 8b-c). In the overweight/obese human sub-
jects, the expression of MVP was negatively correlated with CCL2
in the visceral adipose tissue macrophages (Fig. 6i). These data
suggest that MVP deﬁciency or insufﬁcient expression may sti-
mulate inﬂammatory response by activating NF-κB signaling
pathway in macrophages.
Next, we sought to determine the molecular mechanisms by
which MVP modulates NF-κB signaling pathway in macro-
phages. We ﬁrst tested whether MVP might directly interact
with p65. Co-immunoprecipitation (Co-IP) experiments
showed that MVP did not form a complex with p65
(Supplementary Fig. 9a). Secondly, we investigated the
potential molecular link between MVP and TRAF6, a key
regulator in the activation of NF-κB14. After cell fractionation
by ultracentrifugation, TRAF6 but not TRAF2 or TRAF3
could be detected in the macrophage vault pellet, reﬂecting
that the assembled MVP but not the free MVP may interact
with TRAF6 (Supplementary Fig. 9b-c). Co-IP revealed an
interaction between endogenous MVP and TRAF6 in macro-
phages (Fig. 6j). When both Flag-tagged MVP and HA-tagged
TRAF6 were co-transfected into HEK293T cells, Flag-MVP
was detected mainly in the pellet but not in the supernatant
after cell fractionation, indicating that Flag-MVP may exist as
the assembled vaults in cells. HA-TRAF6 could be co-
precipitated with Flag-MVP in the pellet (Supplementary
Fig. 9d). Co-IP with Flag or HA antibody also showed that
Flag-MVP directly interacted with HA-TRAF6 in cells
(Fig. 6k). Upon LPS stimulation, more TRAF6 was co-
precipitated with the assembled MVP in macrophages after
cell fractionation (Supplementary Fig. 9e) and co-IP with
TRAF6 antibody (Fig. 6l). Furthermore, the MVP–TRAF6
complex formation was enhanced in the obese murine
epiWAT SVFs (Supplementary Fig. 9f). Immunoﬂuorescence
staining showed that MVP predominantly co-localized with
TRAF6 in the cytoplasm of PMs (Fig. 6m).
MVP inhibits the polyubiquitination of TRAF6 in cells. TRAF6
polyubiquitination is a key step in the NF-κB signaling pathway.
Upon LPS stimulation, the E3 ligase activity of TRAF6 is induced
and the activated TRAF6 targets itself and other molecules for
polyubiquitination10,14. MVP depletion signiﬁcantly enhanced
LPS-induced polyubiquitination of TRAF6 in murine BMDMs
(Fig. 7a). In contrast, the overexpression of MVP strongly
inhibited TRAF6 polyubiquitination in HEK293T cells (Fig. 7b).
Therefore, MVP may prevent NF-κB activation via inhibition of
TRAF6 polyubiquitination.
TRAF6 polyubiquitination depends on its recruitment to
IRAK1 and subsequent oligomerization28–30. We found that
MVP deﬁciency increased TRAF6 recruitment to IRAK1 in
BMDMs upon the LPS stimulation (Fig. 7c). Overexpression of
MVP inhibited the complex formation of IRAK1 with TRAF6
(Fig. 7d). Furthermore, the presence of MVP prevented the
TRAF6 oligomerization (Fig. 7e) while IRAK1 promoted TRAF6
oligomerization (Supplementary Fig. 10a) in cells. TRAF6 is
composed of an amino (N)-terminal RING-ﬁnger domain,
several zinc-ﬁnger domains, and a conserved carboxy (C)-
terminal TRAF domain30,31. Considering the structural features
of TRAF6, we generated two truncated fragments of TRAF6
(Supplementary Fig. 10b) both carrying the HA tag. Co-IP
showed that MVP recognized both fragments of TRAF6
(Supplementary Fig. 10c). However, only the C-terminal
fragment (332–530) interacted with IRAK1 (Supplementary
Fig. 10d). This is consistent with the concept that TRAF-C
terminal domain is responsible for the interaction of TRAF6 with
IRAK1 and other signaling molecules13,29,32.
To understand how MVP exerts its inhibitory effects on
TRAF6, we further generated three truncated fragments of MVP
with a Flag tag (Supplementary Fig. 10b). All three expressed
truncates in HEK293T cells existed in both the supernatant and
pellet after cell fractionation, while the full-length MVP (MVP-
FL) was mostly detected in the pellet (Supplementary Fig. 10e).
These three truncated MVPs could bind with TRAF6 (Supple-
mentary Fig. 10f). However, only MVP-FL and MVP α-helical
domain (686–870) could substantially block the oligomerization
(Fig. 7f) and the self-ubiquitination (Fig. 7g) of TRAF6 simulta-
neously. Accordingly, the overexpression of MVP-FL and MVP-
(686–870) strongly inhibited the LPS-induced (Fig. 7h–j) but not
the TNF-α-induced production of inﬂammatory cytokines
(Supplementary Fig. 11a) and the nuclear translocation of p65
(Fig. 7k) in macrophages. MVP-(1–480) and MVP-(481–685) did
not inﬂuence the LPS-induced inﬂammatory cytokines produc-
tion in cells (Supplementary Fig. 11b-c). As such, our data reveal
that MVP suppresses inﬂammatory responses by speciﬁcally
binding to TRAF6 and preventing TRAF6 oligomerization and
ubiquitination in macrophages.
Discussion
Chronic inﬂammation is a common feature of obesity and ather-
osclerosis, and contributes greatly to the pathogenesis of metabolic
Fig. 4MVP deﬁciency promotes inﬂammation in HFD-fed mice. a Representative CD68+ staining in epiWAT from HFD-fed WT andMVP KO mice (n= 5).
Scale bars, 50 μm. b, c Quantiﬁcation of epiWAT SVFs (b) and macrophages (c) by ﬂow cytometry in HFD-fed WT and MVP KO mice (n= 6).
d Representative ﬂow cytometry plot charts of F4/80+CD11b+ macrophages in epiWAT of HFD-fed WT and MVP KO mice. e–i mRNA levels of
inﬂammatory mediators in epiWAT (e), subWAT (f), BAT (g), liver (h) (n= 6–8), and epiWAT F4/80+ macrophages (n= 3) (i) in HFD-fed WT andMVP
KO mice. j Plasma concentrations of TNF-α, IL-6, IL-1β, and CCL2 in HFD-fed WT and MVP KO mice (n= 8). k Representative CD68+ staining in epiWAT
from HFD-fed MacWT and MacKO mice (n= 5). Scale bars, 50 μm. l, m Quantiﬁcation of epiWAT SVFs (l) and macrophages (m) by ﬂow cytometry in
HFD-fed MacWT and MacKO mice (n= 6). n Representative ﬂow cytometry plot charts of F4/80+CD11b+ macrophages in epiWAT of HFD-fed MacWT
and MacKO mice. o–s mRNA levels of inﬂammatory mediators in epiWAT (o), subWAT (p), BAT (q), liver (r) (n= 6–8), and epiWAT F4/80+
macrophages (n= 3) (s) in HFD-fed MacWT and MacKO mice. t Plasma concentrations of TNF-α, IL-6, IL-1β, and CCL2 in HFD-fed MacWT and MacKO
mice (n= 8). Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 by Student’s t test
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diseases. Vast pharmacological efforts have been invested in
developing treatments for metabolic diseases by focusing on pro-
inﬂammatory cytokines as TNF-α, IL-1β, and IL-61,2,33,34. How-
ever, these approaches had limited success. The difﬁculty
in translation underscores the complexity of the metabolic
inﬂammation in the body and highlights a huge gap in the
understanding of the mechanisms underlying metabolic diseases. In
particular, the intrinsic regulatory elements in inﬂammatory path-
ways may fulﬁll an equally critical role in the immunometabolic
homeostasis. In the present study, we have provided a critical proof
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of principle that MVP, the major component of vaults, may act as
an intrinsic inﬂammatory gatekeeper in macrophages to regulate
obesity-associated metabolic disorders and atherosclerosis.
Obesity facilitates the development of many metabolic dis-
orders. On the contrary, weight reduction, achieved through
bypass surgery or otherwise, confers effective therapeutic beneﬁt.
This may also contribute to the underlying core mechanism of
MVP antagonizing insulin resistance, hyperlipidaemia, and liver
steatosis in mice. In addition, we provide evidence to show that
macrophage MVP is the major source of the anti-obesity and
anti-inﬂammatory signal curbing the development of metabolic
disorders, because MVP was up-regulated primarily in macro-
phages and speciﬁc deletion of MVP in macrophages sufﬁced to
aggravate HFD-induced obesity in mice. This unique feature of
MVP separates it from other obesity-associated molecules like
adipocyte fatty-acid-binding protein aP2, which integrates
metabolic and inﬂammatory responses in both adipocytes and
macrophages35. However, the observation that the pro-obesity
effect of MVP deﬁciency in macrophages was somewhat less
prominent compared to that of global MVP deﬁciency in mice
suggests that other sources of MVP may contribute to the early
phase of weight-reducing action. MVP has been shown to be
expressed and functional in endothelial cells and hepatocytes22,25.
The role of other cell and tissue sources of MVP in obesity
warrants to further investigation.
The macrophage-autonomous MVP may be critically involved
in suppressing the magnitude and duration of metabolic
inﬂammation. This conclusion is supported by three key ﬁndings
though the pro-inﬂammatory feature of MVP has been reported
in certain situations36,37: First, MVP deﬁciency caused obvious
macrophage inﬁltration in obese adipose tissues and in athero-
sclerotic lesions in mice. Second, pro-inﬂammatory chemokines
and cytokines were dramatically increased in major metabolic
tissues, in the circulation, and in atherosclerotic lesions of MVP
deﬁciency mice. Third, the loss of MVP strongly activated the
NF-κB signaling pathway in macrophages. In the TLR mediated
inﬂammatory signaling pathway, IRAK1 activated by the MyD88-
dependent pathway recruits TRAF6, promotes its oligomerization
and complex formation with TAB2, TAK1, etc., to undergo
polyubiquitination, thereby activating downstream IKK–NF-
κB11,13,14,29,38. MVP exists and functions as the assembled
macromolecular vault particle in cells19. MVP may bind directly
with TRAF6, which is different from the interaction between
IRAK1 and TRAF6 that promotes TRAF6 oligomerization and
subsequent ubiquitination14,28,29. MVP seems to interact with all
three domains of TRAF6, while IRAK1 interacts only with the
TRAF-C domain13,28. The RING-ﬁnger and zinc-ﬁnger domains
are requisite for the oligomerization and ubiquitination of
TRAF629,32,39. The unique binding pattern of MVP to TRAF6
impairs the oligomerization and ubiquitination of TRAF6. Thus,
MVP may inhibit the IKK–NF-κB signaling by preventing
IRAK1-induced TRAF6 oligomerization and ubiquitination in
macrophages. Yet further studies are needed to elucidate the
detailed molecular mechanisms.
As a suppressor of IKK–NF-κB signaling, it is intrigued that
MVP expression is induced in murine and human macrophages
after the onset of obesity. The observed up-regulation of MVP in
obesity-associated metabolic disorders and atherosclerotic lesions
may be elicited by inﬂammation. The promoter of MVP contains
binding sites for some important pro-inﬂammatory transcription
factors such as SP1 and STAT121,40. Obesity may induce an
insufﬁcient up-regulation of MVP comparing with a strong
induction of inﬂammatory response in the body. Moreover, the
enhanced MVP levels associate with TRAF6 thereby inhibiting its
activation and consequently suppressing NF-κB signaling. All the
three distinct protein domains of MVP could bind to TRAF6. The
α-helical domain of MVP is crucial for the interaction between
MVP molecules and vault assembly41. We demonstrate that
TRAF6 binding to this domain is instrumental in preventing the
oligomerization and ubiquitination of TRAF6. MVP seems not to
interact with TRAF2 or TRAF3. It may not inﬂuence the TNFα-
induced pro-inﬂammatory cytokines production in macrophages.
The selective inhibition of NF-κB up-stream signaling reveals that
MVP may be unable to suppress metabolic inﬂammation com-
pletely. This may partly explain the result that the MVP expres-
sion was negatively correlated with CCL2 but not with TNF-α in
obese human macrophages. Thus, MVP may constitute an
essential constraint in a negative feedback loop to ﬁne-tune
inﬂammatory responses in macrophages, that may contribute to
“low grade and chronic” metabolic inﬂammation.
The role of IKK–NF-κB signaling in metabolic diseases is still a
controversial issue. Although a detrimental role of IKK–NF-κB
activation has been documented in multiple tissues, there have
been conﬂicting results that cannot be neglected. For example,
IKKβ is considered essential in the regulation of adipocyte sur-
vival and adaptive remodeling in obese mice42. In addition, the
IKK–NF-κB pathway can potentially dampen rather than insti-
gate inﬂammation through anti-inﬂammatory cytokine produc-
tion in the adipose tissue and artery43,44. Our study demonstrated
that excessive input of nutrition could activate IKK–NF-κB sig-
naling pathway and inﬂammation in macrophages, which was
strongly attenuated by MVP. Upstream regulators like MVP may
inﬂuence the activity of IKK that would activate NF-κB signaling.
Consistently, leukocyte immunoglobulin-like receptor B4
(LILRB4) recruits SHP1 for inhibiting TRAF6 ubiquitination and
subsequently inactivating NF-κB cascades to attenuate nonalco-
holic fatty liver disease45. Conceivably, the autonomous negative
regulation of TRAF6 by different factors including MVP may
Fig. 5 Deﬁciency of MVP accelerates atherosclerosis progression. a, d En face Oil Red O staining of whole aortas from MVPKOApoEKO (n= 9) and control
MVPWTApoEKO (n= 10) male mice fed with a WD for 10 weeks (a). Lesion occupation was quantiﬁed and shown in (d). b, e Representative H&E-stained
images (b) and quantitative analysis (e) of the lesions in aortic root sections fromMVPKOApoEKO andMVPWTApoEKO mice (n= 9). Quantiﬁcation of lesion
burden was performed by cross-sectional analysis of the aortic root. Scale bars, 200 μm. c, f Representative CD68+ staining in cross-sections (c) and
quantitative analysis (f) of the aortic root plaques fromMVPKOApoEKO andMVPWTApoEKO mice (n= 9). Scale bars, 200 μm. g, j En face Oil Red O staining
of aortas from MVPMacKOApoEKO (n= 10) and control MVPMacWTApoEKO (n= 9) mice fed a WD for 12 weeks (g). Lesion occupation was quantiﬁed and
shown in (j). h, k Representative H&E-stained images (h) and quantitative analysis (k) of the lesions in aortic root sections from MVPMacKOApoEKO and
MVPMacWTApoEKO mice (n= 9). Scale bars, 200 μm. i, l Representative CD68+ staining in cross-sections (i) and quantitative analysis (l) of the aortic root
plaques fromMVPMacKOApoEKO andMVPMacWTApoEKO mice (n= 9). Scale bars, 200 μm.m, n Quantitative analysis of inﬁltrated ﬂuorescent bead-labeled
monocytes in atherosclerotic lesions of MVPKOApoEKO and MVPWTApoEKO mice fed with a WD for 10 weeks (n= 6). o, p Three days after intraperitoneal
injection of 1 ml 4% sterile thioglycollate media, total number of peritoneal cells (o) and F4/80+ PMs (p) of WT andMVP KO mice were measured (n= 5).
q, r mRNA levels of inﬂammatory mediators in the aortas ofMVPKOApoEKO (q) andMVPMacKOApoEKO (r) mice (n= 5–6). s Plasma concentration of TNF-
α, IL-6, IL-1β, and CCL2 in MVPMacKOApoEKO and MVPMacWTApoEKO mice (n= 8). Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 by
Student’s t test
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determine the precise role of IKK and as such the outcomes in the
metabolic diseases.
In summary, our ﬁndings demonstrate that the macrophage
MVP functions as a crucial constraint for metabolic inﬂamma-
tion, in which it attenuates obesity-associated metabolic disorders
and atherosclerosis. Identiﬁcation of autonomous regulatory
mechanism is of special importance for understanding the nature
of inﬂammatory response. This will hopefully open the door to
the development of more effective intervention strategies for the
metabolic diseases.
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Methods
Mice.MVPﬂox/ﬂox mice were generated by Shanghai Model Organisms Center, Inc.
(Shanghai, China), using a targeting vector generated by ET cloning techniques. In
this vector, a neomycin selection cassette ﬂanked by two Frt sites with a loxP site
was inserted into the upstream of exon 2 of the targeted gene. Another loxP site
was inserted into the downstream of exon 3 (Supplementary Fig. 4a). The targeting
vector was electroporated into C57BL/6 Bruce4 embryonic stem (ES) cells. The
correctly recombined ES colony was then injected into C57BL/6 blastocysts. Male
chimeras were mated with female C57BL/6 mice to get mice with a targeted MVP
allele. The mice were crossbred with C57BL/6 ﬂp-recombinase mice to remove the
neomycin cassette to create heterozygous MVPﬂox/+ mice. The mice were then
crossbred with C57BL/6 mice for nine generations before being bred with het-
erozygous MVPﬂox/+ mice to get the MVPﬂox/ﬂox mice. One set of primers were
used to genotype the mice by PCR on DNA isolated from tails (forward 5-
CACAGTGCACATAAACTTATGCAA and reverse 5-TGATGTTCCAAAGGA-
GACAGTAAA), resulting in an 895-bp fragment inMVPﬂox/ﬂox mice and a 771-bp
fragment in WT mice.
To generate myeloid-speciﬁc MVP deﬁcient mice, MVPﬂox/ﬂox mice were
crossed with a C57BL/6J mouse expressing Cre recombinase from the Lyz2
promoter (B6.129P2-Lyz2tm1(cre)Ifo/J), which termed as MacKO (MVPﬂox/ﬂoxLyz2-
Cre) mice. Mice containing the ﬂoxed MVP allele that did not express the Cre
recombinase gene (MVPﬂox/ﬂox) were used as the control (termed as MacWT
mice).
For atherosclerosis experiments, MVP KO mice were subsequently bred with
apolipoprotein E-deﬁcient (ApoE−/−, ApoEKO) mice (B6.129P2-Apoetm1Unc/J) to
generate MVP−/−ApoE−/− (MVPKOApoEKO) mice and their littermates ApoE−/−
(MVPWTApoEKO) mice. For generating myeloid-speciﬁc MVP deﬁcient mice in an
ApoE−/− background, MVPﬂox/ﬂox and Lyz2-Cre mice were ﬁrstly backcrossed
onto the ApoE−/− mice. ApoE−/−MVPﬂox/ﬂox mice were then crossed with ApoE
−/−Lyz2-Cre mice to generate ApoE−/−MVPﬂox/ﬂoxLyz2-Cre mice, which were
termed as MVPMacKOApoEKO mice. ApoE−/−MVPﬂox/ﬂox mice (termed as
MVPMacWTApoEKO mice) were used as controls.
Animal models. Mice were housed at 22–24 °C under standard light conditions
(12 h light/dark cycle) and were allowed free access to water and food. For HFD-
induced obesity model, experimental 7–8-week-old KO mice and their control
mice were fed with either a normal CD or a HFD that contained 60% of its calories
from fat (D12492, Research Diets) for 7 or 12 weeks. Body weight and blood
glucose were measured weekly. For atherosclerosis experiments, experimental male
mice aged 7–8-week-old KO mice and their control mice were fed with a WD that
contained 1.25% cholesterol (D12108C, Research Diets) for 10 or 12 weeks. All
animal protocols were approved by the Institutional Animal Care and Use Com-
mittee of Nanjing Medical University. All relevant ethical regulations were adhered
to.
Human tissue samples. Tissue biopsies from visceral adipose tissue, obtained
during surgery, were stored at −80 °C until further processing. All subjects pro-
vided their written informed consent. All procedures that involved human samples
were approved by the Ethics Committee of Bayi Clinical Medicine School of
Nanjing Medical University. All relevant ethical regulations were followed. To
examine MVP expression, parafﬁn sections were stained with an anti-MVP anti-
body (Santa Cruz, sc-18701, 1:50). To isolate SVFs, human adipose tissues were
digested using collagenase type II (1.5 mg ml−1, Sigma) at 37 °C for 40 min. After
passing cells through a 200 μm cell strainer and centrifugation at 1000g for 10 min,
the pellet containing the SVFs was then incubated with red blood cell lysis buffer.
SVFs were resuspended in phosphate-buffered saline (PBS) supplemented with 1%
fetal bovine serum (FBS, Gibco). CD14+ macrophages were puriﬁed using mag-
netic beads (BD Biosciences), according to the manufacturer’s instructions. Cells
were immediately used for total RNA extraction.
Cell culture. Primary mouse PMs and BMDMs were isolated and maintained as
described46,47. PMs were harvested from the peritoneal cavity, washed with PBS,
resuspended in Roswell Park Memorial Institute (RPMI, Gibco) 1640 medium
containing 10% (v/v) FBS, supplemented with 1% penicillin/streptomycin (P/S). After
2 h incubation at 37 °C, nonadherent cells were removed, and the remaining adherent
cells were cultured. To isolate BMDMs, 3–4-week-old mice were euthanized, and
their femurs and tibias were collected. Bone marrow cells were cultured and differ-
entiated for 7 days in RPMI 1640 medium supplemented with 10% FBS, 1% P/S,
and 20 ngml−1 M-CSF (Sigma-Aldrich). Cells were treated with 100 ngml−1 lipo-
polysaccharide (LPS, Sigma-Aldrich) or 10 ngml−1 TNF-α (R&D Systems) for
indicated times for analysis. RAW264.7 and HEK293T cells (ATCC) were cultured
in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) supplemented with 10% FBS and
1% P/S.
Intraperitoneal glucose and insulin tolerance tests. Following an overnight fast,
about 16 h, mice were intraperitoneally injected with glucose (1.5 g kg−1), and
blood samples for glucose determination were collected from the tail vein at the
indicated times. Insulin tolerance was assessed after a 6 h fast by intraperitoneal
injection of human regular insulin (1 U kg−1) and blood glucose monitoring.
Glycemia was assessed using the OneTouch Horizon Glucose Monitoring kit
(LifeScan).
In vivo insulin signaling. For examination of in vivo insulin signaling, mice were
fasted for 6 h, i.p. injected with human regular insulin (1 U kg−1). Subsequently,
mice were anesthetized and euthanized, and epiWAT, liver, and skeletal muscle
were collected at the indicated times, ﬂash-frozen in liquid nitrogen and stored at
−80 °C until for western blot analysis with antibodies against phosphorylated AKT
and total AKT.
Analysis of metabolic parameters. Blood glucose levels were measured using the
OneTouch Horizon Glucose Monitoring kit (LifeScan) via tail vein blood sampling.
Plasma insulin level in mice was measured using an insulin ELISA kit (Mercodia,
Sweden). Plasma nonesteriﬁed fatty acids (NEFA), triglycerides (TG), total-
cholesterol (TCH), low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C), AST, ALT and liver TG, TCH concentration were
measured by using the enzymatic assays according to the manufacturer’s instruc-
tions (Jiancheng Bio, China). Plasma TNF-α, IL-6, IL-1β, and CCL2 (eBioscience)
concentration were determined by ELISA.
Quantiﬁcation of atherosclerosis burden. Mice were euthanized and perfused
with PBS through the left ventricle. Hearts and aortas were removed carefully and
ﬁxed with 4% paraformaldehyde. For en face analysis, the entire aorta was opened
longitudinally, stained with Oil Red O, then placed on a blank sheet of paper and
photographed with a Canon camera (PowerShot G12). Percentage of Oil Red O
positive area was calculated using ImagePro Plus software. Hearts were dissected
from the aorta and embedded in Tissue-Tek OCT compound (Sakura Finetek). For
morphology analysis, aortic roots were cut in 5 μm-thick serial cryosections
beginning from the onset of the aortic valves until the valves disappeared. Sections,
each 80–100 μm apart, were mounted on one slide. Lesion size was quantiﬁed after
H&E staining and calculated as the averages of 3 independent sections using
ImagePro Plus software. Samples which exhibited evidence of artefactual tissue
damage or abnormal orientation that could not be compensated by the analysis of
multiple independent sections were excluded from analysis.
Monocyte recruitment assays. For the monocyte inﬁltration into atherosclerotic
lesion assay, experimental male mice were fed a WD for 10 weeks. Clodronate-
liposomes (250 μl, Liposoma) were i.v. injected in order to transiently deplete
monocytes, followed by i.v. injection of 250 μl ﬂuorescent microspheres 48 h later.
Fig. 6 MVP deﬁciency activates IKK–NF-κB signaling. PMs isolated from CD-fed WT and MVP KO mice were treated with LPS (100 ngml−1) for indicated
times. a, b PMs were stimulated with LPS for 12 h and mRNA levels of inﬂammatory mediators (TNF-α and CCL2) were assessed by RT-qPCR (n= 3)
(a). TNF-α and CCL2 levels in culture media were determined using ELISA (n= 3) (b). c, d Western blot analysis of p-IKK, IKK, IκBα, p-p65, and p65 in
PMs that were treated with LPS for indicated times (n= 3). e, f Western blot analysis of nuclear extracts prepared from PMs stimulated with LPS for the
indicated times and analyzed for p65 and Lamin B1 (n= 3). g Representative immunoﬂuorescence images of p65 nuclear translocation assay. PMs were
stimulated with LPS for 3 h and analyzed for p65 localization by immunoﬂuorescence staining. Nuclei were stained with DAPI, and the percentage of
nuclear p65 positive cells was counted. Scale bars, 10 μm. hmRNA levels of inﬂammatory mediators in PMs cultured with or without LPS or NF-κB pathway
inhibitor BAY11-7082 (n= 3). i Correlative analysis of the expression of MVP versus TNF-α and CCL2 in CD14+ macrophages from the visceral adipose
tissue of overweight/obese human subjects (n= 24). j Co-IP and western blot analysis of endogenous MVP and TRAF6 from protein lysates of murine
BMDMs. k HEK293T cells were transfected with control Flag empty vector or Flag-MVP and HA-TRAF6 plasmids (left), and control HA empty vector or
HA-TRAF6 and Flag-MVP plasmids (right). Co-IP and western blot analysis with anti-HA and anti-Flag antibodies. l Co-IP and quantiﬁcation of the
interaction between MVP and TRAF6 in response to LPS stimulation in BMDMs. m Representative immunoﬂuorescence images of PMs stained by anti-
MVP (red) and anti-TRAF6 (green) antibodies to examine the distribution of MVP and TRAF6. Scale bars, 10 μm. Representative results from three
independent experiments are shown. Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01 by Student’s t test or ANOVA with post hoc test
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Fluoresbrite FITC-dyed (YG, 0.5 μm) plain microspheres (2.5% solids [w/v];
Polysciences) were diluted 1:25 in PBS26,27. Mice were euthanized and hearts with
aortic root was then used for consecutive sections from the atrioventricular valve at
a thickness of 20 μm. Nuclei were counter-stained by DAPI Fluor mount-G
(SouthernBiotech). Images were then captured using a ﬂuorescence microscope
(Carl Zeiss). Beads that reﬂect monocyte recruitment were quantiﬁed in 3–5 aortic
sinus sections per mouse.
For the murine peritoneal mono-macrophage recruitment, 1ml of sterile 4%
thioglycolate media was injected intra-peritoneally. The cells from murine peritoneal
cavities were harvested 3 days later, and analyzed by cell counter or ﬂow cytometry.
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Histological analysis. Formalin-ﬁxed, parafﬁn-embedded tissue sections were
routinely stained with H&E for the evaluation of the tissue morphology. The frozen
liver sections were prepared using Tissue-Tek OCT compound (Sakura Finetek)
and subjected to Oil Red O staining (Sigma-Aldrich) to visualize lipid droplets. The
histological features were observed and captured under a light microscope (Carl
Zeiss).
For immunohistochemical (IHC) staining, sections were incubated with
primary antibodies against MVP (Santa Cruz, sc-18701, 1:50) and CD68 (Bio-Rad,
MCA1957, 1:100) followed by incubation with the secondary antibodies conjugated
with horseradish peroxidase. The sections were then treated with the ABC staining
system (Santa Cruz) according to the instructions of the manufacturer. For all
sections, 3,3-diaminobenzidine was used as the indicator substrate, which appeared
as a brown reaction product. For immunoﬂuorescence analysis, anti-MVP (goat,
Santa Cruz, sc-18701, 1:50), anti-CD68 (rat, Bio-Rad, MCA1957, 1:100), anti-
perilipin (rabbit, Cell Signaling, 9349, 1:100), anti-p-p65 (rabbit, Cell Signaling,
3033, 1:100), anti-p65 (rabbit, Cell Signaling, 8242, 1:100), and anti-TRAF6 (rabbit,
Absin, abs115194, 1:100, China) antibodies were applied. The secondary antibodies
were Alexa Fluor 546 donkey anti-goat IgG, Alexa Fluor 488 donkey anti-rat IgG,
Alexa Fluor 647 donkey anti-rabbit IgG, Alexa Fluor 546 donkey anti-rabbit IgG,
and Alexa Fluor 488 donkey anti-rabbit IgG (Thermo Fisher Scientiﬁc). Nuclei
were counter-stained by DAPI Fluor mount-G (SouthernBiotech). Images were
then captured using a ﬂuorescence microscope (Carl Zeiss) or confocal microscope
(Carl Zeiss) and analyzed. At least ﬁve samples per group were analyzed by
ImagePro Plus software in each experiment.
Flow cytometry analysis. SVFs were isolated from mice epiWAT, resuspended in
PBS supplemented with 1% FBS and stained with indicated ﬂuorescent isotope-
conjugated antibodies for 30 min at room temperature in the dark. The antibodies
used for FACS included anti-F4/80-BV421 (BD Biosciences, 565411) and anti-
CD11b-FITC (BD Biosciences, 553310). For PMs recruitment analysis, mice were
euthanized 3 days after injection of 4% sterile thioglycollate media (Sigma-Aldrich).
Cells were harvested from the peritoneal cavity, washed with PBS, and incubated
with PE-conjugated anti-F4/80 (R&D Systems, FAB5580P) antibody. The cells
marked with the antibodies were then washed three times with PBS. Samples were
analyzed using FACS Verse (BD Biosciences). For sorting F4/80+ macrophages
from SVFs, FACS Aria II (BD Biosciences) was used.
Subcellular fractionation by ultracentrifugation. Cell fractionation was done
with modiﬁcations as reported48. After lysis of the cells in lysis buffer for 10 min on
ice, cells were centrifuged at 20,000g for 15 min. The post-nuclear supernatant
fraction was centrifuged at 100,000g for 1 h. The resulting supernatant was
designated as the S fraction (supernatants, S fraction). All pellets were resuspended
by lysis buffer and protease inhibitors in the original volume (pellets, P fraction).
Equal volume amounts of fractions were analyzed by western bolt.
Co-immunoprecipitation. Cells were lysed in co-IP buffer containing protease
inhibitor cocktail tablets (Roche, Germany). The cell lysates were incubated with
the indicated antibody at 4 °C overnight. Next day, the cell lysates were conjugated
with protein A/G beads (Santa Cruz) for 4–6 h. Immunoprecipitates were collected,
washed three times in lysis buffer at 4 °C, and eluted into Laemmli sample buffer by
boiling. The immunocomplex was subjected to western blot using the indicated
antibodies. Antibodies applied for co-IP included anti-p65 (Cell Signaling, 8242),
anti-TRAF6 (Thermo Fisher Scientiﬁc, 38-0900), anti-Flag (Sigma-Aldrich, F1804),
and anti-HA (Thermo Fisher Scientiﬁc, 26183).
RT-qPCR analysis. Total RNA was isolated from tissues and puriﬁed cells using
RNAiso Plus (TaKaRa, Japan). The quality of the RNA samples was reverse
transcribed into cDNA using commercial kits (Vazyme Biotech, China). RT-qPCR
was performed using the ABI Prism 7000 PCR system (Applied Biosystems) and
analysis was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Primers are listed in Supplementary Table 1.
Western blot analysis. Cell lysates or immunoprecipitates were separated by SDS-
PAGE and transferred to PVDF membranes. After blocking with 5% BSA, the
membrane was incubated with primary antibodies at 4 °C overnight, followed by
incubation with the corresponding secondary antibodies for 1 h at room tem-
perature. The membranes were washed three times for 10 min each, incubated with
SuperSignal chemiluminescent substrate (Pierce) and imaged by ChemiDoc XRS+
Imaging System (Bio-Rad). Blots were semi-quantiﬁed using ImageJ software. The
following antibodies were used: MVP (Santa Cruz, sc-23916, 1:100), MVP (Santa
Cruz, sc-18701, 1:100), phospho-AKT (Cell Signaling, 9271, 1:1000), AKT (Cell
Signaling, 9272, 1:1000), phospho-IKKα/β (Cell Signaling, 2697, 1:1000), IKKα/β
(Santa Cruz, sc-7607, 1:500), IκBα (Cell Signaling, 4814, 1:1000), phospho-p65
(Cell Signaling, 3033, 1:1000), p65 (Cell Signaling, 8242, 1:1000), TRAF6 (BioLe-
gend, 654502, 1:1000), Flag (Sigma-Aldrich, F1804, 1:1000), HA (Roche,
11867423001, 1:1000), HA (Thermo Fisher Scientiﬁc, 26183, 1:5000), TRAF2 (Cell
Signaling, 4724, 1:1000), TRAF3 (Santa Cruz, sc-6933, 1:200), Ub (Millipore,
MAB1510, 1:1000), IRAK1 (Santa Cruz, sc-5288, 1:200), Myc (Cell Signaling, 2278,
1:1000), His (Cell Signaling, 12698, 1:1000), α-Tubulin (Protein Tech, 11224-1-AP,
1:1000), GAPDH (Kangchen Tech, KC-5G4, 1:3000), β-actin (Santa Cruz, sc-
47778, 1:1000), Lamin B1 (Protein Tech, 66095-1-Ig, 1:1000). Nuclear extract
preparation was conducted according to the manufacturer’s instructions of a
commercial kit (Thermo Fisher Scientiﬁc). Uncropped blots are available in Sup-
plementary Fig. 12.
Statistical analysis. Differences between groups were examined for statistical
signiﬁcance using the Student’s t test or analysis of variance (ANOVA). All sta-
tistical tests were performed using GraphPad Prism 6.0, and all data are repre-
sented as mean ± SEM. Group comparisons were assessed with Student’s t test to
compare two groups, and ANOVA followed by post hoc test for multiple com-
parisons as appropriate. For all tests, P < 0.05 was deﬁned as signiﬁcant.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data supporting the ﬁndings of this study are available within the main manuscript
and the supplementary ﬁles, or from the corresponding author upon reasonable request.
A reporting summary for this article is available as a supplementary ﬁle.
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